# AUPH catalysts: Aurinia Pharmaceuticals Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/auph/catalysts

> Aurinia Pharmaceuticals Inc. (AUPH) has no upcoming catalysts in this calendar. The latest recorded is the Aurinia Pharmaceuticals Inc. earnings report, October 30, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Aurinia Pharmaceuticals Inc. |
| Ticker | AUPH (Nasdaq) |
| SEC CIK | 1600620 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/auph |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 22, 2021 | [Lupkynis (voclosporin) FDA approval](https://sec-api.dev/pdufa/voclosporin) | AUPH |  | completed, approved | "NDA213716 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name AURINIA; product LUPKYNIS (VOCLOSPORIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213716%22)) |
| April 29, 2024 | [Lupkynis (voclosporin) label expansion decision](https://sec-api.dev/pdufa/voclosporin) | AUPH |  | completed, approved | "NDA213716 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20240429, review_priority STANDARD; sponsor_name AURINIA; product LUPKYNIS (VOCLOSPORIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213716%22)) |
| Sep 2024 | [Aritinercept trial start](https://sec-api.dev/pdufa/aritinercept) | AUPH |  | completed | "In September 2024, Aurinia initiated a Phase 1 study of AUR200, its potentially best-in-class dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/exhibit991_q42024pressrele.htm)) |
| February 27, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/exhibit991_q42024pressrele.htm)) |
| May 12, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/exhibit991_q12025earningsr.htm)) |
| July 3, 2025 | [Lupkynis (voclosporin) primary completion](https://sec-api.dev/pdufa/voclosporin) | AUPH | Adolescent Lupus Nephritis; Pediatric Lupus Nephritis | withdrawn | "NCT05288855 (Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Aurinia Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05288855)) |
| July 4, 2025 | [Lupkynis (voclosporin) primary completion](https://sec-api.dev/pdufa/voclosporin) | AUPH | Adolescent Lupus Nephritis; Pediatric Lupus Nephritis | withdrawn | "NCT05962788 (Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Aurinia Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05962788)) |
| July 31, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000090/exhibit991_q22025earningsr.htm)) |
| November 4, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/exhibit991_q32025earningsr.htm)) |
| February 26, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/exhibit991_q42025earningsr.htm)) |
| May 7, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm)) |
| August 6, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/exhibit991_q22026earningsr.htm)) |
| October 30, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000074/exhibit991_q32026earningsr.htm)) |

## Drugs

- [Aritinercept](https://sec-api.dev/pdufa/aritinercept): 
- [Lupkynis (voclosporin)](https://sec-api.dev/pdufa/voclosporin): Adolescent Lupus Nephritis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/auph/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AUPH catalysts: Aurinia Pharmaceuticals Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/auph/catalysts

```bibtex
@misc{secapidev_companies_auph_catalysts_20261116,
  title        = {AUPH catalysts: Aurinia Pharmaceuticals Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/auph/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_auph_catalysts_20261116","title":"AUPH catalysts: Aurinia Pharmaceuticals Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/auph/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
